Principal Scientist
Simcyp, Certara UK Ltd
Dr. Xian Pan is a Principal Scientist at Certara UK Ltd, Simcyp Division.
Her academic journey began with a BSc in Pharmacy and an MSc in Pharmacokinetics from China Pharmaceutical University, earning a Ph.D. after in Biopharmaceutical Sciences from the University of Illinois at Chicago. Her doctoral work focused on the altered pharmacokinetics during pregnancy, specifically investigating the molecular mechanisms of CYP2D6 induction, CYP activity alteration in intrahepatic cholestasis, and inter-individual variability of CYP2D6.
With extensive industry experience in leading preclinical drug metabolism and pharmacokinetic projects, Dr. Pan has significantly contributed to PBPK platform enhancement at Simcyp, including various modules development and expansion for small molecule drugs and therapeutic proteins, and evaluation of drug-drug interaction liabilities for both modalities. She has actively contributed to the expansion of the virtual populations for Japanese and Chinese paediatrics, premature neonates, and foetus. Moreover, she has provided PBPK consultancy for critical drugs targeting tuberculosis, COVID-19, malaria, sickle cell anaemia and Prader-Willi syndrome. Her recent scientific efforts have focused on utilising PBPK models to optimise dosing for paediatric, maternal, and breastfeeding populations, considering genetic polymorphism, nutritional status, and ethnic diversity.
She is also the Chair of the Specific Populations (SPO) Community within ASCPT and serves on the Editorial Board of CPT: Pharmacometrics & Systems Pharmacology.
Friday, May 30, 2025
8:15 AM - 9:15 AM East Coast USA Time